-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 12th, Hangzhou Qiming Medical Instrument Co.
, Ltd.
, China's leading provider of integrated heart valve interventional treatments, announced that the company will be included in the MSCI China Index, effective after the market closes on May 27, 2021
.
The MSCI China Index is compiled by MSCI, an internationally renowned index compiling company, and has a very balanced selection of industries, especially in industries such as medical biology and technology
.
The index covers companies with good business performance and development potential.
The results of the semi-annual index review in May 2021 showed that 60 new constituent stocks were added to the MSCI China Index and 21 were removed at the same time
.
Among them, 21 overseas Chinese stocks are included, and Qiming Medical is also included.
Financial report data shows that despite the impact of the new crown pneumonia epidemic, Qiming Medical will still achieve sales revenue of 276 million yuan in 2020 through its professional advantages, an increase of 18.
3% year-on-year
.
A total of about 2,200 TAVR operations were completed throughout the year, a year-on-year increase of more than 50%
At present, Qiming Medical has a complete product layout in the field of structural heart disease treatment, and provides an overall solution of "brain protection-balloon-valve".
The company's full series of "China Smart" valve products have entered nearly 30 worldwide Countries and regions throughout Asia, Europe, South America and North America
.
The company will continue to devote itself to the research and development and commercialization of structural heart disease therapeutic medical devices, and make continuous efforts to provide safer and more effective clinical solutions
